193090-61-8 Usage
Uses
Used in Pharmaceutical Industry:
Benzonitrile, 4-amino-2,3-dichlorois used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Dye Industry:
In the dye industry, Benzonitrile, 4-amino-2,3-dichloroserves as a key intermediate in the production of various dyes. Its chemical properties enable the creation of dyes with specific color characteristics and stability.
Used in Agricultural Chemicals Industry:
Benzonitrile, 4-amino-2,3-dichlorois utilized as an intermediate in the synthesis of agricultural chemicals, such as pesticides and herbicides. Its presence in these products contributes to their effectiveness in controlling pests and weeds in agricultural settings.
Check Digit Verification of cas no
The CAS Registry Mumber 193090-61-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,0,9 and 0 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 193090-61:
(8*1)+(7*9)+(6*3)+(5*0)+(4*9)+(3*0)+(2*6)+(1*1)=138
138 % 10 = 8
So 193090-61-8 is a valid CAS Registry Number.
193090-61-8Relevant academic research and scientific papers
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Hamann, Lawrence G.,Manfredi, Mark C.,Sun, Chongqing,Krystek Jr., Stanley R.,Huang, Yanting,Bi, Yingzhi,Augeri, David J.,Wang, Tammy,Zou, Yan,Betebenner, David. A.,Fura, Aberra,Seethala, Ramakrishna,Golla, Rajasree,Kuhns, Joyce E.,Lupisella, John A.,Darienzo, Celia J.,Custer, Laura L.,Price, Jennifer L.,Johnson, James M.,Biller, Scott A.,Zahler, Robert,Ostrowski, Jacek
, p. 1860 - 1864 (2008/02/04)
Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.
